Orange Juice Consumption in Patients With Hepatitis C
キーワード
概要
説明
Forty-three patients with chronic hepatitis C who were being treated with pegylated interferon combined with ribavirin, according to the Clinical Protocol and Therapeutic Guidelines for Viral Hepatitis C and Co-infections of the Brazilian Health Ministry were randomly divided into two parallel groups: (1) orange juice (n = 23), which were supplemented with orange juice (500 mL/d) for 8 weeks; (2) control group (n = 20) composed of patients that were not drinking orange juice regularly. The recruitment process began in February 2012, the intervention was carried out from May 2012 to July 2012, and the data analysis started in September 2012. The sample number took into account variances on total cholesterol with a type I error α = 0.05 and a type II error β = 0.2 (80% power) (Dourado et al., 2015). The minimum sample size should have 20 individuals per group (n = 40), considering an approximately 15% dropout rate. Primary and secondary endpoints were the reduction of total cholesterol and modification of biochemical markers, respectively. Kolmogorov Smirnov and Levene test assessed normality and homogeneity of data, respectively. Assessment of the data was performed in all participants on the first and last day of the experiment. All the parameters were compared between the juice group and the control group using General Linear Model of Repeated Measures Analysis. Differences in baseline patients' characteristics between the two groups were analyzed by One-way analysis of variance (ANOVA). The LSD signed rank post-test was used to assess significant changes in parameters after the start of treatment in each group, and the differences were considered statistically significant at p < 0.05.
日付
| 最終確認済み: | 12/31/2016 |
| 最初に提出された: | 01/16/2017 |
| 提出された推定登録数: | 01/16/2017 |
| 最初の投稿: | 01/19/2017 |
| 最終更新が送信されました: | 01/19/2017 |
| 最終更新日: | 01/22/2017 |
| 実際の研究開始日: | 04/30/2012 |
| 一次完了予定日: | 06/30/2012 |
| 研究完了予定日: | 08/31/2012 |
状態または病気
介入/治療
Other: Orange juice
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Experimental: Orange juice Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks. | Other: Orange juice The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment. |
| No Intervention: Control Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks. |
適格基準
| 研究の対象となる年齢 | 18 Years に 18 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: - Detection of circulating HCV RNA - Negative HBV surface antigen - Negative antibodies to HIV Exclusion Criteria: - Co-infection with hepatitis B virus (HBV) - Co-infection with hepatitis A virus (HAV) - Co-infection with human immunodeficiency virus (HIV) - Presence of diabetes mellitus, - Presence of ascites - Elevation in serum ferritin levels |
結果
主な結果の測定
1. Total cholesterol [8 weeks]
二次的な結果の測定
1. Body mass [8 weeks]
2. Body mass index [8 weeks]
3. % body fat [8 weeks]
4. Waist circumference [8 weeks]
5. Glucose [8 weeks]
6. Insulin [8 weeks]
7. HOMA-IR [8 weeks]
8. LDL-C [8 weeks]
9. HDL-C [8 weeks]
10. Triglycerides [8 weeks]
11. CRP [8 weeks]
12. alkaline phosphatase [8 weeks]
13. AST [8 weeks]
14. ALT [8 weeks]
15. gamma-GT [8 weeks]
16. TBARS [8 weeks]
17. ABTS [8 weeks]
